General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2021-12-23 | 2021-09 | -0.32 | N/A | N/A | N/A |
2021-08-12 | 2021-06 | -0.31 | N/A | N/A | N/A |
2021-05-12 | 2021-03 | -0.24 | N/A | N/A | N/A |
2021-03-04 | 2020-12 | -0.22 | N/A | N/A | N/A |
2020-11-12 | 2020-09 | -0.16 | N/A | N/A | N/A |
2020-08-11 | 2020-06 | -0.19 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2021-06-02 | Roth Capital | Downgrade | Buy | Neutral |
2021-05-13 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
2020-07-15 | Cantor Fitzgerald | Upgrade | Overweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2020-06-29 | REMEDITEX VENTURES, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2021-09-29 | Sio Capital Management, LLC | 824.80K | 16.79M | 3.82% |
2021-09-29 | Blackrock Inc. | 731.48K | 14.89M | 3.39% |
2021-09-29 | Vanguard Group, Inc. (The) | 619.76K | 12.62M | 2.87% |
2021-09-29 | Polar Asset Management Partners Inc. | 568.31K | 11.57M | 2.63% |
2021-09-29 | Millennium Management LLC | 493.60K | 10.05M | 2.29% |
2021-09-29 | First Trust Capital Management L.P. | 373.00K | 7.59M | 1.73% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2021-09-29 | First Tr Exchange Traded Fd-First Trust Merger Arbitrage Fd | 369.46K | 7.52M | 1.71% |
2021-09-29 | Vanguard Total Stock Market Index Fund | 304.17K | 6.19M | 1.41% |
2021-10-30 | iShares Russell 2000 ETF | 270.51K | 5.57M | 1.25% |
2021-09-29 | Vanguard Extended Market Index Fund | 145.64K | 2.97M | 0.67% |
2021-10-30 | iShares Russell 2000 Growth ETF | 90.34K | 1.86M | 0.42% |
2021-09-29 | IndexIQ Tr-IQ Merger Arbitrage ETF | 81.86K | 1.67M | 0.38% |
HOUSTON, Nov. 21, 2019 /PRNewswire/ -- Soliton, Inc., (Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center ("MD Anderson"), today announced that it has entered into a Cooperative Development Agreement with Emphysys, an interdisciplinary technology and product development firm just outside Boston, for design and engineering services related to the Company's acoustical shockwave technology.
Under the terms of the agreement, Emphysys will provide engineering and design services related to shockwave technology for use in dermatology and aesthetics fields to Soliton for a three-year period.
Dr. Chris Capelli, Soliton President, CEO and co-founder comments, "This partnership with Emphysys protects Soliton's development efforts as we move through the coming stages of commercialization. Emphysys was instrumental to the early development of our technology and their continued involvement helps to ensure that we launch a robust, capable device. Our latest device iteration is designed with both the removal of tattoos and the reduction of cellulite in mind and we are excited to begin efforts towards a commercially viable platform device with Emphysys' support."
Emphysys, Inc. is a technology and product development partner to leading companies and emerging startups in the Medical Device, Life Science, and Industrial markets. With unmatched expertise in fundamental science, multi-modal energy generation, software control systems, and sophisticated simulation and modeling capabilities, the company's interdisciplinary teams of world-class engineers and scientists focus on developing highly complex technology and energy-based products on unprecedented time scales.
Ali Shajii, President and CEO of Emphysys, said, "We value our long-term partnership with Soliton and are excited to continue our collaboration on this pioneering new technology. Our shared mindset of developing and delivering truly differentiable products makes this a remarkable partnership."
For more information about Emphysys, please visit: www.emphysys.com
Rich: $SOLY They are doing follow up appointments now for cellulite.
Cellulite indication for FDA APPROVAL will not be given until the first or 2nd Qtr of 2020. However, we will have RAP for tattoos rolling out Qtr 1 of 2020. This will help stabilize stock price around $20-$30 in my opinion.
6 coming soon
$SOLY The Company’s cash, cash equivalents and restricted cash on hand of $8,708,641 as of September 30, 2019 and subsequent closing of approximately $5,700,000 in net proceeds from the Company's private placement with certain institutional and accredited investors on October 11, 2019 are sufficient to fund the Company's operations through the third quarter of 2020 but not beyond. The Company also believes it will need to raise additional capital in order to continue to execute its business plan, including obtaining additional regulatory clearance for its products currently under development and commercializing and generating revenues from products under development. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company. A failure to raise sufficient capital will adversely impact the Company’s ability to meet its financial obligations as they become due and payable and to achieve its intended business objectives. If the Company is unable to raise sufficient additional funds, it will have to scale back its operations.